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Abstract (250 words) 
Background 
Patients undergoing carotid endarterectomy (CEA) for symptomatic stenosis of the internal 
carotid artery (ICA) benefit from early intervention. Heterogeneous data are available on the 
influence of timing of carotid artery stenting (CAS) on procedural risk. 
Methods 
We investigated the association between timing of treatment (0-7 days and >7 days after the 
qualifying neurological event) and the 30-day risk of stroke or death after CAS or CEA in a 
pooled analysis of individual patient data from four randomized trials by the Carotid Stenosis 
Trialists’ Collaboration (CSTC). Analyses were done per protocol. To obtain combined 
estimates, logistic mixed models were applied. 
Results 
Among 4138 patients in both treatment groups, a minority received their allocated treatment 
within seven days after symptom onset (14% CAS versus 11% CEA). Among patients 
treated within one week of symptoms, those treated by CAS had a higher risk of stroke or 
death compared to with those treated with CEA: 8.3% vs 1.3%, risk ratio (RR) 6.7, 95% CI 
2.1-21.9 (adjusted for age at treatment, sex and type of qualifying event). For interventions 
after one week, CAS was also more hazardous than CEA: 7.1% vs 3.6%, adjusted RR 2.0, 
95% CI 1.5-2.7. The p value for interaction between timing of treatment and treatment 
technique was 0.06. 
Interpretation  
In randomized trials comparing stenting with carotid endarterectomy for symptomatic carotid 
artery stenosis, CAS was associated with a substantially higher periprocedural risk during the 
first seven days after the onset of symptoms. Early surgery is safer than stenting for 
preventing future stroke. 
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Background 
Carotid artery stenting (CAS) has evolved as an alternative treatment for carotid artery 
disease. Over the last 20 years, CAS has striven to prove its feasibility and efficacy in stroke 
prevention when compared with that of carotid endarterectomy (CEA) for patients with 
symptomatic internal carotid artery (ICA) stenosis. Because of the high risk of early stroke 
recurrence after plaque rupture, it is now accepted that intervention offers the greatest 
benefit when performed soon after the onset of neurological symptoms1, 2. The somewhat 
greater perioperative risk of rapid CEA is offset by a much lower risk of stroke recurrence3. 
Timing of treatment could also influence the results of carotid artery stenting. Unlike early 
surgery, CAS seems to be a higher risk procedure when performed soon after symptoms. 
The 2012 analysis based on individual patient-level data from three randomized trials 
comparing CAS and CEA reported by the Carotid Stenosis Trialists’ Collaboration (CSTC) 
suggested that timing of intervention influenced the occurrence of endpointsoutcomes. CAS 
between day 0 and 7 was associated with the highest number of procedural complications 
when compared with patients treated between 8 and 14 days, or thereafter. In contrast, 
surgery during each of these time intervals was safer4.  
In this updated analysis, we added data from individual patients with symptomatic carotid 
stenosis from the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST). This 
provided the largest group yet studied of patients with symptomatic carotid stenosis 
randomized between CEA and CAS, and enabled us to investigate associations between 
periprocedural outcome and timing of treatment for both techniques. 
  
Commented [AA3]: I reserve ‘endpoint’ for fatal outcomes; a 
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Methods 
Four randomized clinical trials with blinded adjudicated endpoints outcomes were included; 
EVA-3S (NCT 00190398), SPACE (ISRCTN 57874028), and ICSS (ISRCTN 25337470) and 
CREST (NCT 00004732). In the first 3 of these trials, patients with symptomatic moderate to 
severe carotid stenosis (>50% stenosis measured according to NASCET criteria5), deemed 
suitable for both procedures, were randomly allocated to CAS or CEA 6-8. Our pooled 
analysis of individual patient data was prospectively agreed at the design stage of the three 
European trials 9. Data on symptomatic patients from CREST were added in 2015.  CREST 
included patients with transient ischaemic attack (TIA), amaurosis fugax and minor non-
disabling ischaemic stroke. To be eligible for CREST, patients had to have a carotid artery 
stenosis of at least 50% (on invasive angiography), of 70% or more (when detected by 
ultrasound or computed tomography angiography) or of 50-69% (on ultrasound or magnetic 
resonance angiography) 10. 
The primary outcome for the present analysis was the combination of any stroke or death 
occurring within 30 days after treatment. Secondary outcome events were any stroke and 
fatal or disabling stroke happening within the same time period. The analysis was done per-
protocol: patients were only included in the analysis if the randomly allocated treatment was 
the first initiated revascularization procedure and if either the date of the qualifying event (the 
last ischaemic event ipsilateral to the carotid artery being randomized in the trial), or the 
interval between the qualifying event and treatment was known. Patients with missing data 
on delay between qualifying event and treatment were excluded from the analysis.  
In three studies (EVA-3S, ICSS and CREST), the date of the qualifying event was entered at 
baseline. In the SPACE trial the date of the qualifying event was not prospectively assessed 
at study entry, however, the date of the qualifying event was retrospectively retrieved 
whenever possible for this pooled analysis. If the exact date was unknown, patients were 
included if information was available whether treatment had taken place within seven days of 
the qualifying event or thereafter. 
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Statistical Analysis 
To obtain a combined estimate (risk ratio (RR) with 95% confidence intervals (CI)), logistic 
mixed models were applied with the study as random variable using a log-link. The first 
model was unadjusted whereas the second model accounted for age at treatment, sex, and 
type of qualifying event (retinal ischaemia, TIA, or stroke). Age at treatment was log-
transformed based on the natural logarithm (ln) in the mixed model analysis. In contrast to 
our previous analysis, just two timing groups were created, because results of patients 
treated between 8-14 days or thereafter were similar, irrespective of the treatment 
technique4. Therefore the primary analysis compared patients treated within 7 days of 
neurological symptoms or thereafter. Secondly, an interaction between timing of treatment 
and treatment effect (CAS versus CEA) was tested by integrating a multiplicative interaction 
term in the logistic mixed model analyses. A p value of <0.10 for interaction terms was 
considered statistically significant, for all other statistical analyses a p-value of <0.05 was 
considered to indicate statistical significance. 
 
Results 
Baseline characteristics 
The pooled data set for all four trials included 4754 patients with symptomatic ICA stenosis. 
2361 patients were randomized to CEA (49.7%) and 2393 patients to CAS. For both 
treatment groups a number of patients were excluded from data analysis due to missing 
information about their most recent neurological event, or the treatment date (n=290 patients 
in the CEA group and n=274 in the CAS group). Another 52 patients (26 in each treatment 
group) were excluded because they did not receive the initially allocated treatment. Figure 1 
gives detailed information about included and excluded patients by source trial. In total, 4138 
patients (n=2045 in the CEA and 2093 in the CAS group) remained for per protocol analysis. 
Table 1 summarizes the baseline characteristics of both treatment groups. The median delay 
between the most recent neurological event and treatment was 26 days [interquartile range: 
11-61] for CAS and 29 days [interquartile range: 13-67] for CEA. Among 4138 patients, a 
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small but relevant group underwent CAS and CEA within a week of their symptoms (14% in 
CAS vs. 11% in CEA). Treatment groups did not differ for neurological parameters and 
comorbidities. Baseline characteristics were additionally provided for the two timing groups 
(Table 2). 
 
Overall outcome in the study population for both treatment groups (CAS vs. CEA)  
The risk of any stroke or death within 30 days after treatment was higher for the CAS 
compared withto the CEA group for the entire study population: 7.3% vs. 3.3%, crude RR 
2.29, 95% CI 1.71-3.08. This association remained significant when the model was 
additionally adjusted for age at treatment, sex and type of qualifying event (RR 1.92, 95% CI 
1.50-2.47).  
 
Outcome in both treatment groups by timing of treatment (0-7 days and > 7 days) 
In the early period after the onset of neurological symptoms (0 to 7 days), CAS had the 
highest number and proportion of periprocedural strokes and deaths (n=24/287, 8.4%), 
compared with CEA (n=3/226, 1.3%). Patients in the CAS group had a higher risk of any 
stroke or death in the crude (RR 6.51, 95% CI 2.00-21.21) and adjusted models (RR 6.74, 
95% CI 2.07-21.92) (Figure 2).  
Compared withto those treated within 7 days, patients treated after 7 days had fewer strokes 
and deaths in the CAS group (n=129/1806, 7.1%), while the risk of stroke and death in the 
CEA group slightly increased (n=65/1819, 3.6%). The risk ratio for CAS compared with CEA 
was still higher in this later treatment group: RRcrude 2.00, 95% CI 1.49-2.67; RRadjusted 2.00, 
95% CI 1.50-2.68. Results were almost identical for the outcome analysis of any stroke: 
RRcrude for CAS in the early treatment group 6.27, 95% CI 1.92-20.44; RRcrude for CAS after 7 
days 1.98, 95% CI 1.47-2.67 (Table 3). Adjustment did not importantly change results (Figure 
2). The analysis of fatal or disabling stroke outcome at 30 days also showed that the crude 
risk ratio was higher for CAS than the CEA group within 7 days (RR 8.29, 95% CI 1.07-
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64.28) and after 7 days (RR 1.77, 95% CI 1.10-2.85) (Table 3). Results were virtually 
unchanged after adjustment (Figure 2). 
 
Interaction between time and relative risks of CAS versus CEA 
The test for interaction between timing of treatment and treatment effect (CAS versus CEA) 
revealed a p value of 0.07 in the crude and 0.06 in the adjusted model for the outcome any 
stroke or death. Comparable results were seen for the outcome any stroke at 30 days (p 
value for both models=0.07). There was no statistically significant interaction seen for fatal or 
disabling stroke (Figure 2). 
 
Discussion 
Carotid artery stenting is not as safe as carotid endarterectomy in the treatment of patients 
with symptomatic stenosis of the internal carotid artery irrespective of the timing of treatment. 
The difference in safety between CAS and CEA is particularly potent in patients treated 
within 7 days of symptom onset. 
There has been a heated debate as to whether early surgery in symptomatic patients is safe 
and meaningful. However, it is now widely accepted that early plaque removal effectively 
reduces stroke risk. Although early surgery may be associated with a slightly higher risk of 
perioperative complications, it still offers the best chance of a symptomatic patient avoiding 
future stroke3, 11. Recent literature suggests that the risk of early recurrent stroke from 
symptomatic ICA stenosis remains high12-14. In a very recently published series of 377 
patients with symptomatic ICA stenosis stroke recurrence rate reached 2.7% within the first 
day, 5.3% within three days and 18.8% within 90 days after the qualifying event14. Only one 
retrospective Swedish study reported a lower overall number of second events in 397 
patients with symptomatic stenosis of the ICA (for recurrent stroke 2.0%, 95% CI 0.6-3.4 by 
day 2, 2.4%, 95% CI 2.0-5.9 by day 7 and 7.5%, 95% CI 4.4-10.6 by day 30)15.  
The same group published results from the SWEDVASC registry where the outcome of CEA 
was analyzed depending on the timing of treatment. The authors found that rapid surgery 
Commented [AA6]: ‘important’ is a better alternative?? 
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(between 0-2 days) was associated with a significantly higher frequency of perioperative 
complications (any stroke or death) when compared with patients treated between 3 and 7 
days, 8 and 14 days and thereafter (11.5% vs. 3.6% vs. 4.0% vs. 5.4%, p<0.001, 
respectively)16. Only a small number of SWEDVASC patients were treated in the very early 
period (5.7%), which might limit the generalizability of these registry data. In contrast, their 
slight increase in perioperative complications was not replicated in two single center studies 
17, 18. Both studies reported comparable perioperative complication rates for the same four 
surgical timing groups. The analysis of more than 56.000 patients with symptomatic ICA 
stenosis from the German nationwide statutory quality assurance registry also revealed no 
outcome difference between patients treated early (within 48 hours) and thereafter (any 
stroke or death 3.0% for CEA between 0-2 days vs. 2.5% between 3-7 days vs. 2.6% 
between 8-14 days vs. 2.3% for CEA thereafter)19. Also results from the National Vascular 
Registry from the UK illustrated comparable results for the four timing groups among more 
than 23.000 symptomatic patients20. Complementary to this register data which only 
contained CEA patients very recently results from the National (Nationwide) Inpatient Sample 
(NIS) were published. In this analysis authors investigated the influence of ultra-early 
revascularizations (within 48 hours) on the outcome of CAS and CEA in more than 70.000 
symptomatic patients. The comparison between CAS and CEA when performed within 48 
hours after the onset of symptoms showed that CAS was associated with significantly more 
periprocedural complications, regardless of whether patients had a cerebral infarction on 
admission or not (OR 3.45, 95% CI 3.13-3.80, p>0.01 for CAS patients with infarct on 
admission compared withto CEA under same conditions; OR 2.53, 95% CI 2.40-2.66, 
p<0.001 for CAS patients without infarct on admission compared withto CEA again under 
same conditions)21. These authors did not find any outcome differences after later treatment 
for both CEA and CAS. Recently the influence of timing on the outcome of CAS and CEA 
was also analyzed in the CREST data. The authors used three timing groups (CAS or CEA 
<15 days, 15-60 days and thereafter) and did not see any time-dependence for 
periprocedural outcome for both treatment techniques (HR for stroke or death in the CAS 
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group comparing 15-60d days to <15 days 1.15, 95% CI 0.48-2.75 and 1.12, 95% CI 0.53-
2.40 comparing >60days to <15 days, both p=0.93). For the CEA group comparing 15-60d 
days to <15 days the HR was 0.74, 95% CI 0.22-2.49 and 0.91, 95% CI 0.25-3.33, 
respectively, comparing >60days to <15 days, both p=0.89)22. Differences in outcome 
analysis between CREST only and CSTC plus CREST data might be due to different time 
strata, making results more difficult to compare. 
In the present report we found that the CAS group had the highest periprocedural stroke or 
death risk in the period of 0-7 days after the onset of symptoms compared withto patients 
treated with CEA. CAS was also associated with a significantly higher risk in the later 
treatment period (> 7 days). Early surgery had the lowest absolute number of periprocedural 
complications for all three endpointsoutcomes. CAS complications slightly decreased with 
time (for primary outcome any stroke or death from 8.4% to 7.1%). This result is consistent 
with the hypothesis that the plaque surface of a recently symptomatic plaque is fragile and 
vulnerable for catheter passage. The clinical decision to perform either CAS or CEA early is 
likely influenced by characteristics of the patient and the symptomatic event. We saw in both 
treatment groups that the percentage of patients treated following a hemispheric stroke was 
about 10% higher in the later treatment group compared withto early treated patients (Table 
2). Patients within the timing groups did not differ for neurological parameters. Since timing of 
treatment was not of note when the four randomized trials were conducted in the early years 
of the new millennium the slight increase in the procedural risk for CEA over time (any stroke 
or death 1.3% for 0-7 days vs. 3.6% for CEA after 7 days) might be by chance.   
In another analysis of the NIS, the authors focused on patients with symptomatic ICA 
stenosis and recent cerebral infarction. Analyses were done in four timing groups: CEA or 
CAS within 48 hours after the onset of symptoms, between 48 hours and 4 days, between 5 
and 7 days and between 8 and 14 days. Amongst the 27839 patients with recent cerebral 
infarction, patients treated between five and seven days after symptoms had the lowest 
probability of periprocedural complications (OR 0.64, 95% CI 0.56-0.74, p<0.001) and 
mortality (OR 0.63, 95% CI 0.45-0.89, p<0.001), irrespective of the treatment technique23. 
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Without having details about cerebral lesions we found in the CSTC population that CEA was 
most beneficial when performed between 0 and 7 days, whereas CAS was most harmful 
during the first week after the onset of symptoms. Due to small numbers of patients who 
were treated early after the onset of symptoms and relatively small numbers of 
periprocedural complications in both treatment groups we could not build further time groups 
to determine an ideal time point for CAS and CEA amongst our study population.  
 
Limitations of our analysis 
Timing of treatment has to date never been a randomization criterion in larger trials. All 
information on the influence of timing of treatment is driven from post hoc analysis from 
randomized controlled trials comparing two treatment techniques (best medical treatment vs. 
CEA or CEA vs. CAS). Therefore, detailed information on patient selection and disease 
severity is lacking. This significantly limits the value of timing analysis so far. A randomized 
trial on timing of treatment would be mandatory in the near future.  
Recent ischaemic infarction on neuroimaging is reported to be a relevant risk factor for 
periprocedural complications after CAS as well as after CEA.  Unfortunately, detailed findings 
from baseline CT or MRI were not available for the present analysis.  
 
Conclusion 
Carotid endarterectomy is very effective at preventing stroke. Early plaque removal can be 
performed without relevantly increasing perioperative complications. In contrast, carotid 
artery stenting during the early period after plaque rupture is associated with an increased 
risk of periprocedural complications. We could clearly demonstrate in this randomized and 
large population of symptomatic patients that risk differences between CAS and CEA were 
greatest in the early days after the index symptom. Early CEA was associated with the 
lowest risk of periprocedural complications. We therefore conclude that early carotid 
endarterectomy after an initial neurological event offers the highest stroke prevention benefit 
for the patient at risk. 
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Table 1 Baseline data of the combined trial population according to treatment group (CAS and CEA) 
 
CAS 
n=2093 
CEA 
n=2045 p value 
Age at treatment (years)  
69.4±9.2 
[63,70,76] 
69.5±9.3 
[63,70,77] 
0.49 
Male, n (%) 1449 (69) 1442 (71) 0.37 
History of diabetes, n (%) 519 (25) 507 (25) 0.997 
History of hypertension, n (%) 1570 (75) 1552 (76) 0.56 
History of hypercholesterolemia, n (%)a 1142
 a, (55) 1172 a (57) 0.06 
Any smoking history (current/past), n (%) 1317 (63) 1310 (64) 0.44 
History of coronary heart disease, n (%) 572 (27) 576 (28) 0.49 
History of peripheral artery disease, n (%)b 173
 a (8) 161 a (8) 0.52 
Degree of ipsilateral carotid stenosis, n (%)c   
 
Moderate (50-69%) 366 b (17) 369b (18) 
0.64 Severe (70-99%) 1727 b (83) 1676 b (82) 
Contralateral severe carotid stenosis (>70%) or 
occlusion, n (%)c 
208 b (10) 204 b (10) 
0.94 
Type of most recent ipsilateral ischaemic event 
before randomization, n (%)    
TIA 774 (37) 761 (37) 
0.95 
Retinal ischaemia 363 (17) 347 (17) 
Hemispheric stroke 942 (45) 923 (45) 
modified Rankin Score (mRS) at baselined    
mRS=0 , n (%) 1033 (49) 994 (49) 
0.79 
mRS=1 , n (%) 564 (27) 539 (26) 
mRS=2 , n (%) 334 (16) 342 (17) 
mRS=3 , n (%) 114 (5) 124 (6) 
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Mean ± standard deviation (SD) and [25th, 50th, 75th percentile] in case of non-normal distribution; interquartile range (IQR): 25th - 75th percentile] or number (%) (=percent excluding 
missing values) 
CAS: carotid artery stenting, CEA: carotid endarterectomy; TIA: transient ischemic attack 
a Data collected in EVA-3S, ICSS and CREST only. 
b Data collected in EVA-3S and ICSS only. 
c Degree of stenosis measured by NASCET method or equivalent non-invasive method. 
d Modified Rankin Scores at baseline may reflect non-stroke impairments; protocols of contributing trials excluded patients with disabling strokes. 
e The date of the most recent ipsilateral ischaemic event before randomization was not collected in the SPACE trial initially, but for the meta-analysis these dates (or if the exact 
date was unknown, whether or not randomization and treatment took place within 7 days of the qualifying event), were retrieved where available. 
 
  
mRS=4 , n (%) 26 (1)  24 (1) 
mRS=5 , n (%) 1 (0.05) 3 (0.1) 
History of stroke before most recent event, n (%)b 371 a (18) 365 a (18) 0.93 
Days elapsed between most recent ipsilateral 
ischaemic event and treatmente 
45.5±50.6 
[11,26,61] 
49.8±59.1 
[13,29,67] 0.004 
Treatment within 7 days of most recent event e 287 (14) 226 (11) 0.009 
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 0-7 days >7 days 
 CAS 
n=287 
CEA 
n=226 
CAS 
n=1806 
CEA 
n=1819  
Age at randomization (years)  
68.3±9.0 
[62,69,75] 
69.2± 8.9 
[63,70,76] 
69.6±9.2 
[63,70,77] 
69.6±9.4 
[63,70,77] 
Male, n (%) 198 (69) 157 (69) 1251 (69) 1285 (71) 
History of diabetes, n (%) 82 (29) 55 (24) 437 (24) 452 (25) 
History of hypertension, n (%) 220 (77) 189 (84) 1350 (75) 1363 (75) 
History of hypercholesterolemia, n (%)a 164 (57) 123 (54) 978 (54) 1049 (58) 
Any smoking history (current/past), n (%) 191 (67) 146 (65) 1126 (62) 1164 (64) 
History of coronary heart disease, n (%) 89 (31) 77 (34) 483 (27) 499 (27) 
History of peripheral artery disease, n (%)a 12 (4) 11 (5) 161 (9) 150 (8) 
Degree of ipsilateral carotid stenosis, n 
(%)b     
Moderate (50-69%) 54 (19) 38 (17) 312 (17) 331 (18) 
Severe (70-99%) 233 (81) 188 (83) 1494 (83) 1488 (82) 
Contralateral severe carotid stenosis 
(>70%) or occlusion, n (%)b 16 (5.6) 14 (6.2) 192 (11) 190 (10) 
Type of most recent ipsilateral ischaemic 
event before randomization, n (%)     
TIA 146 (51) 112 (50) 628 (35) 649 (36) 
Retinal ischaemia 37 (13) 30 (13) 326 (18) 317 (17) 
Hemispheric stroke 101 (35) 83 (37) 841 (47) 840 (46) 
modified Rankin Score (mRS) at baselinec     
mRS=0 , n (%) 138 (48) 119 (53) 895 (50) 875 (48) 
mRS=1 , n (%) 91 (32) 68 (30) 473 (26) 471 (26) 
mRS=2 , n (%) 38 (13) 32 (14) 296 (16) 310 (17) 
mRS=3 , n (%) 13 (5) 4 (2) 101 (6) 120 (7) 
mRS=4 , n (%) 4 (1) 1 (0.4) 22 (1) 23 (1) 
mRS=5 , n (%) 0 (0) 0 (0) 1 (0.06) 3 (0.2)  
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Mean ± standard deviation (SD) and [25th, 50th, 75th percentile] in case of non-normal distribution; interquartile range (IQR): 25th - 75th percentile] or number (%) (=percent excluding 
missing values) 
CAS: carotid artery stenting, CEA: carotid endarterectomy; TIA: transient ischaemic attack 
 
  
History of stroke before most recent event, 
n (%)a 43 (15) 
 
28 (12) 328 (33) 337 (33) 
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Table 3: Logistic mixed models of two treatment groups (CAS vs. CEA) depending on timing of treatment (0-7 days and >7 days) on three different 
outcomes within 30 days after treatment (any stroke or death, any stroke and fatal or disabling stroke).  
 
CEA 
n event/ n total (%) 
CAS 
n event/ n total (%) 
Crude RR 
(95% CI) * 
p-value 
Any stroke or death 
0-7 days  3/226 (1.3)  24/287 (8.4)  6.51 (2.00-21.21) 0.002 
>7 days  65/1819 (3.6)  129/1806 (7.1)  2.00 (1.49-2.67) <0.0001 
Any stroke 
0-7 days 3/226 (1.3)  23/287 (8.0)  6.27 (1.92-20.44) 0.002 
>7 days 62/1819 (3.4)  122/1806 (6.8)  1.98 (1.47-2.67) <0.0001 
Fatal or disabling stroke 
0-7 days  1/226 (0.4)  9/287 (3.1)  8.29 (1.07-64.28) 0.04 
>7 days 26/1819 (1.4)  46/1806 (2.5)  1.77 (1.10-2.85) 0.02 
* CEA represents reference group. 
CAS: carotid artery stenting, CEA: carotid endarterectomy, CI: confidence interval  
 
Commented [AA8]: Also these p-values may be deleted as 
they are redundant when presenting the effect estimate and 
95% CI. 
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4754 patients randomly
assigned in four trials
274 missing dates of the
most recent ischemic
event or PP_initiated=0*
2361 patients assigned
to CEA
2393 patients assigned
to CAS
290 missing dates of the
most recent ischemic
event or PP_initiated=0*
26 PP_initiated=0*26 PP_initiated=0*
2093 remaining for PP 
analysis#1
0-7 d 287 (13.7%)
>7d 1806 (86.3%)
2045 remaining for PP 
analysis#2
0-7d 226 (11.1%)
>7d 1819 (88.9%)
 
Figure 1: Flow diagram of patients included in the meta analysis referring to source trial 
PP_initiated=0 reflects patients who did not receive the primarily allocated treatment technique. Those patients 
were excluded for per protocol analysis 
#1  2093 CAS patients: 260 (12.4%) EVA-3S, 381 (18.2%) SPACE, 828 (39.6%) ICSS, 624 (29.8%) CREST;  
#2  2045 CEA patients: 257 (12.6%) EVA-3S, 365 (17.8%) SPACE, 819 (40.0%) ICSS, 604 (29.5%) CREST  
PP: per protocol, CAS: carotid artery stenting, CEA: carotid endarterectomy
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Figure 2: Forest plot illustrating the adjusted relative risk of two treatment groups (CAS vs. CEA) in two timing groups (0-7 days and >7 days) on 
three different outcomes within 30 days after treatment (any stroke or death, any stroke and fatal or disabling stroke). Model adjusted for age at 
treatment, sex, and type of qualifying event (retinal ischaemia, TIA, or stroke). 
 
